Maternal Oxygen Supplementation for Fetal Distress
(MOXY Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether giving oxygen to pregnant women in labor benefits babies showing signs of stress, compared to breathing regular air. The researchers aim to determine if oxygen supplementation (also known as Maternal Oxygen Supplementation) is safe and effective for both babies and mothers during labor. This study is crucial because current medical guidelines disagree on the use of oxygen in these situations. Women who are at least 37 weeks pregnant, in labor, and carrying a single baby are suitable candidates for this trial. As an unphased trial, it offers participants the chance to contribute to vital research that could clarify medical guidelines and improve care for future mothers and babies.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your healthcare provider.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Past studies have not clearly established the safety of giving oxygen to mothers during labor. Some research has shown that short periods of oxygen can alter the baby's blood flow, but the effects remain uncertain. Other studies suggest that oxygen might impact the baby's acid-base balance, which is crucial for health. Experts continue to debate whether using oxygen for fetal distress is safe and beneficial. More high-quality research is needed to provide clear answers.12345
Why are researchers excited about this trial?
Researchers are excited about exploring maternal oxygen supplementation for addressing fetal distress because it offers a potentially immediate intervention that is non-invasive and widely accessible. Unlike other treatments for fetal distress, which may involve more invasive procedures or medications, administering oxygen to the mother can be a simple and fast way to improve fetal oxygenation. This approach could provide a safer and more convenient option for both mothers and babies, particularly in emergency situations where time is critical.
What evidence suggests that maternal oxygen supplementation could be effective for fetal distress?
This trial will compare Maternal Oxygen Supplementation with Room Air for fetal distress. Research has shown insufficient evidence to determine if extra oxygen for mothers during labor benefits their babies. Some studies suggest that oxygen does not improve an abnormal fetal heart rate. Consequently, uncertainty remains about oxygen's effectiveness for the baby. Experts hold differing opinions on using oxygen in these situations. More research is needed to determine if oxygen can truly make a difference.12456
Are You a Good Fit for This Trial?
This trial is for pregnant women at or beyond 37 weeks of gestation, in spontaneous labor or induction, who speak English or Spanish and are having single babies with planned continuous fetal monitoring. It excludes those scheduled for cesarean delivery, with the most severe fetal heart rate issues (Category III), major fetal anomalies, multiple pregnancies, maternal oxygen levels below 95%, or preterm gestation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either oxygen supplementation or room air during labor with Category II EFM
Follow-up
Participants are monitored for neonatal and maternal morbidity outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Maternal Oxygen Supplementation
- Room Air
Maternal Oxygen Supplementation is already approved in United States, European Union for the following indications:
- Intrauterine resuscitation in cases of indeterminate or abnormal fetal heart rate patterns
- Intrauterine resuscitation in cases of indeterminate or abnormal fetal heart rate patterns
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
University of Michigan
Collaborator
University of Texas at Austin
Collaborator
Women and Infants Hospital of Rhode Island
Collaborator
Dell Children's Medical Center of Central Texas
Collaborator
Brown University
Collaborator